

OSCIENT PHARMACEUTICALS CORP  
Form 8-K  
August 10, 2004

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): August 10, 2004

---

# OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts  
(State or other jurisdiction of incorporation)

0-10824  
(Commission File Number)

04-2297484  
(I.R.S. Employer Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

Page 1 of 4 pages.

**ITEM 5. OTHER EVENTS**

On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing the completion of its Phase II clinical trial of Ramoplanin for the treatment of *Clostridium difficile*-associated diarrhea, which is attached hereto as Exhibit 99.1.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

99.1 Press Release issued by Oscient Pharmaceuticals Corporation on August 10, 2004.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OSCIENT PHARMACEUTICALS CORPORATION

By: /s/ Stephen Cohen  
Name: Stephen Cohen

Title: Senior Vice President and

Chief Financial Officer

Date: August 10, 2004

**EXHIBIT INDEX**

**Exhibit Number**

**Description**

99.1

Press Release issued by Oscient Pharmaceuticals Corporation on August 10, 2004.